Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Cyclophilin A Function in Mammary Epithelium Impacts Jak2/Stat5 Signaling, Morphogenesis, Differentiation, and Tumorigenesis in the Mammary Gland.

Volker SE, Hedrick SE, Feeney YB, Clevenger CV.

Cancer Res. 2018 Jul 15;78(14):3877-3887. doi: 10.1158/0008-5472.CAN-17-2892. Epub 2018 Jun 29.

PMID:
29959151
2.

Evaluating Nonclinical Performance of the Academic Pathologist: A Comprehensive, Scalable, and Flexible System for Leadership Use.

Wiles AB, Idowu MO, Clevenger CV, Powers CN.

Acad Pathol. 2018 Feb 1;5:2374289518754889. doi: 10.1177/2374289518754889. eCollection 2018 Jan-Dec.

3.

Aberrantly high expression of the CUB and zona pellucida-like domain-containing protein 1 (CUZD1) in mammary epithelium leads to breast tumorigenesis.

Mapes J, Anandan L, Li Q, Neff A, Clevenger CV, Bagchi IC, Bagchi MK.

J Biol Chem. 2018 Feb 23;293(8):2850-2864. doi: 10.1074/jbc.RA117.000162. Epub 2018 Jan 10.

PMID:
29321207
4.

A pilot study of cabergoline for the treatment of metastatic breast cancer.

Costa R, Santa-Maria CA, Scholtens DM, Jain S, Flaum L, Gradishar WJ, Clevenger CV, Kaklamani VG.

Breast Cancer Res Treat. 2017 Oct;165(3):585-592. doi: 10.1007/s10549-017-4370-x. Epub 2017 Jul 3.

PMID:
28674764
5.

Histone H1 and Chromosomal Protein HMGN2 Regulate Prolactin-induced STAT5 Transcription Factor Recruitment and Function in Breast Cancer Cells.

Schauwecker SM, Kim JJ, Licht JD, Clevenger CV.

J Biol Chem. 2017 Feb 10;292(6):2237-2254. doi: 10.1074/jbc.M116.764233. Epub 2016 Dec 29.

6.

NSG Mice Provide a Better Spontaneous Model of Breast Cancer Metastasis than Athymic (Nude) Mice.

Puchalapalli M, Zeng X, Mu L, Anderson A, Hix Glickman L, Zhang M, Sayyad MR, Mosticone Wangensteen S, Clevenger CV, Koblinski JE.

PLoS One. 2016 Sep 23;11(9):e0163521. doi: 10.1371/journal.pone.0163521. eCollection 2016.

8.

HDAC6 Deacetylates HMGN2 to Regulate Stat5a Activity and Breast Cancer Growth.

Medler TR, Craig JM, Fiorillo AA, Feeney YB, Harrell JC, Clevenger CV.

Mol Cancer Res. 2016 Oct;14(10):994-1008. Epub 2016 Jun 29.

9.

Engineering synthetic antibody binders for allosteric inhibition of prolactin receptor signaling.

Rizk SS, Kouadio JL, Szymborska A, Duguid EM, Mukherjee S, Zheng J, Clevenger CV, Kossiakoff AA.

Cell Commun Signal. 2015 Jan 15;13:1. doi: 10.1186/s12964-014-0080-8.

10.

Immunoassay and Nb2 lymphoma bioassay prolactin levels and mammographic density in premenopausal and postmenopausal women the Nurses' Health Studies.

Rice MS, Tworoger SS, Bertrand KA, Hankinson SE, Rosner BA, Feeney YB, Clevenger CV, Tamimi RM.

Breast Cancer Res Treat. 2015 Jan;149(1):245-53. doi: 10.1007/s10549-014-3232-z. Epub 2014 Dec 13.

11.

Bioactive prolactin levels and risk of breast cancer: a nested case-control study.

Tworoger SS, Rice MS, Rosner BA, Feeney YB, Clevenger CV, Hankinson SE.

Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):73-80. doi: 10.1158/1055-9965.EPI-14-0896. Epub 2014 Oct 14.

12.

Antipsychotic treatment in breast cancer patients.

Rahman T, Clevenger CV, Kaklamani V, Lauriello J, Campbell A, Malwitz K, Kirkland RS.

Am J Psychiatry. 2014 Jun;171(6):616-21. doi: 10.1176/appi.ajp.2013.13050650. Review.

PMID:
24880509
13.

Comment on "Progesterone/RANKL is a major regulatory axis in the human breast".

Wang J, Gupta A, Hu H, Chatterton RT, Clevenger CV, Khan SA.

Sci Transl Med. 2013 Dec 11;5(215):215le4. doi: 10.1126/scitranslmed.3006883.

14.

Hormonal determinants of nipple aspirate fluid yield among breast cancer cases and screening controls.

Fought AJ, McGathey C, Scholtens DM, Heinz RE, Lowe R, Feeney YB, Lee O, Kmiecik TE, Wolfman JA, Clevenger CV, Gann PH, Gapstur S, Chatterton RT, Khan SA.

Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2277-84. doi: 10.1158/1055-9965.EPI-12-0434. Epub 2013 Sep 18.

15.

The prolactin receptor transactivation domain is associated with steroid hormone receptor expression and malignant progression of breast cancer.

Fiorillo AA, Medler TR, Feeney YB, Wetz SM, Tommerdahl KL, Clevenger CV.

Am J Pathol. 2013 Jan;182(1):217-33. doi: 10.1016/j.ajpath.2012.09.021. Epub 2012 Nov 14.

16.

Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells.

Wu AM, Dalvi P, Lu X, Yang M, Riddick DS, Matthews J, Clevenger CV, Ross DD, Harper PA, Ito S.

Mol Pharmacol. 2013 Feb;83(2):377-88. doi: 10.1124/mol.112.082362. Epub 2012 Nov 13.

17.

A humanized pattern of aromatase expression is associated with mammary hyperplasia in mice.

Zhao H, Pearson EK, Brooks DC, Coon JS 5th, Chen D, Demura M, Zhang M, Clevenger CV, Xu X, Veenstra TD, Chatterton RT, DeMayo FJ, Bulun SE.

Endocrinology. 2012 Jun;153(6):2701-13. doi: 10.1210/en.2011-1761. Epub 2012 Apr 16.

18.

Negative cross talk between NFAT1 and Stat5 signaling in breast cancer.

Zheng J, Fang F, Zeng X, Medler TR, Fiorillo AA, Clevenger CV.

Mol Endocrinol. 2011 Dec;25(12):2054-64. doi: 10.1210/me.2011-1141. Epub 2011 Sep 29.

19.

HMGN2 inducibly binds a novel transactivation domain in nuclear PRLr to coordinate Stat5a-mediated transcription.

Fiorillo AA, Medler TR, Feeney YB, Liu Y, Tommerdahl KL, Clevenger CV.

Mol Endocrinol. 2011 Sep;25(9):1550-64. doi: 10.1210/me.2011-0106. Epub 2011 Aug 4.

20.

Prolactin receptor-integrin cross-talk mediated by SIRPα in breast cancer cells.

Galbaugh T, Feeney YB, Clevenger CV.

Mol Cancer Res. 2010 Oct;8(10):1413-24. doi: 10.1158/1541-7786.MCR-10-0130. Epub 2010 Sep 8.

21.

Reproducibility of plasma and urine biomarkers among premenopausal and postmenopausal women from the Nurses' Health Studies.

Kotsopoulos J, Tworoger SS, Campos H, Chung FL, Clevenger CV, Franke AA, Mantzoros CS, Ricchiuti V, Willett WC, Hankinson SE, Eliassen AH.

Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):938-46. doi: 10.1158/1055-9965.EPI-09-1318. Epub 2010 Mar 23. Erratum in: Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1805.

22.

Cyclophilin B as a co-regulator of prolactin-induced gene expression and function in breast cancer cells.

Fang F, Zheng J, Galbaugh TL, Fiorillo AA, Hjort EE, Zeng X, Clevenger CV.

J Mol Endocrinol. 2010 Jun;44(6):319-29. doi: 10.1677/JME-09-0140. Epub 2010 Mar 17.

23.

New mechanisms for PRLr action in breast cancer.

Clevenger CV, Gadd SL, Zheng J.

Trends Endocrinol Metab. 2009 Jul;20(5):223-9. doi: 10.1016/j.tem.2009.03.001. Epub 2009 Jun 15. Review.

PMID:
19535262
24.

Cyclophilins contribute to Stat3 signaling and survival of multiple myeloma cells.

Bauer K, Kretzschmar AK, Cvijic H, Blumert C, Löffler D, Brocke-Heidrich K, Schiene-Fischer C, Fischer G, Sinz A, Clevenger CV, Horn F.

Oncogene. 2009 Aug 6;28(31):2784-95. doi: 10.1038/onc.2009.142. Epub 2009 Jun 8.

PMID:
19503092
25.

Expression of cyclophilin B is associated with malignant progression and regulation of genes implicated in the pathogenesis of breast cancer.

Fang F, Flegler AJ, Du P, Lin S, Clevenger CV.

Am J Pathol. 2009 Jan;174(1):297-308. doi: 10.2353/ajpath.2009.080753. Epub 2008 Dec 4.

26.

Role of c-Myb during prolactin-induced signal transducer and activator of transcription 5a signaling in breast cancer cells.

Fang F, Rycyzyn MA, Clevenger CV.

Endocrinology. 2009 Apr;150(4):1597-606. doi: 10.1210/en.2008-1079. Epub 2008 Nov 26.

27.

Energy balance, early life body size, and plasma prolactin levels in postmenopausal women.

Su X, Hankinson SE, Clevenger CV, Eliassen AH, Tworoger SS.

Cancer Causes Control. 2009 Mar;20(2):253-62. doi: 10.1007/s10552-008-9240-8. Epub 2008 Oct 14.

28.

Prolyl isomerase cyclophilin A regulation of Janus-activated kinase 2 and the progression of human breast cancer.

Zheng J, Koblinski JE, Dutson LV, Feeney YB, Clevenger CV.

Cancer Res. 2008 Oct 1;68(19):7769-78. doi: 10.1158/0008-5472.CAN-08-0639.

29.

The isolation of novel mesenchymal stromal cell chemotactic factors from the conditioned medium of tumor cells.

Lin SY, Yang J, Everett AD, Clevenger CV, Koneru M, Mishra PJ, Kamen B, Banerjee D, Glod J.

Exp Cell Res. 2008 Oct 15;314(17):3107-17. doi: 10.1016/j.yexcr.2008.07.028. Epub 2008 Aug 8.

30.

Quantification of PRL/Stat5 signaling with a novel pGL4-CISH reporter.

Fang F, Antico G, Zheng J, Clevenger CV.

BMC Biotechnol. 2008 Feb 6;8:11. doi: 10.1186/1472-6750-8-11.

31.

Prolactin stimulates ubiquitination, initial internalization, and degradation of its receptor via catalytic activation of Janus kinase 2.

Swaminathan G, Varghese B, Thangavel C, Carbone CJ, Plotnikov A, Kumar KG, Jablonski EM, Clevenger CV, Goffin V, Deng L, Frank SJ, Fuchs SY.

J Endocrinol. 2008 Feb;196(2):R1-7. doi: 10.1677/JOE-07-0554.

PMID:
18252943
32.

From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics.

Clevenger CV, Zheng J, Jablonski EM, Galbaugh TL, Fang F.

J Mammary Gland Biol Neoplasia. 2008 Mar;13(1):147-56. doi: 10.1007/s10911-008-9074-8. Epub 2008 Feb 2. Review.

PMID:
18246318
33.

Altered expression of prolactin receptor-associated signaling proteins in human breast carcinoma.

McHale K, Tomaszewski JE, Puthiyaveettil R, Livolsi VA, Clevenger CV.

Mod Pathol. 2008 May;21(5):565-71. doi: 10.1038/modpathol.2008.7. Epub 2008 Feb 1.

34.

Nek3 kinase regulates prolactin-mediated cytoskeletal reorganization and motility of breast cancer cells.

Miller SL, Antico G, Raghunath PN, Tomaszewski JE, Clevenger CV.

Oncogene. 2007 Jul 12;26(32):4668-78. Epub 2007 Feb 12.

PMID:
17297458
35.

The kinetics of binding human prolactin, but not growth hormone, to the prolactin receptor vary over a physiologic pH range.

Keeler C, Jablonski EM, Albert YB, Taylor BD, Myszka DG, Clevenger CV, Hodsdon ME.

Biochemistry. 2007 Mar 6;46(9):2398-410. Epub 2007 Feb 6.

PMID:
17279774
36.

Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications.

Gadd SL, Clevenger CV.

Mol Endocrinol. 2006 Nov;20(11):2734-46. Epub 2006 Jul 13.

PMID:
16840534
37.

Stabilization of prolactin receptor in breast cancer cells.

Li Y, Clevenger CV, Minkovsky N, Kumar KG, Raghunath PN, Tomaszewski JE, Spiegelman VS, Fuchs SY.

Oncogene. 2006 Mar 23;25(13):1896-902.

PMID:
16278670
38.
39.

Signal transduction.

Clevenger CV.

Breast Dis. 2003;18:1. No abstract available.

PMID:
15687683
40.

Novel association of Vav2 and Nek3 modulates signaling through the human prolactin receptor.

Miller SL, DeMaria JE, Freier DO, Riegel AM, Clevenger CV.

Mol Endocrinol. 2005 Apr;19(4):939-49. Epub 2004 Dec 23.

PMID:
15618286
41.
43.

A novel and functional interaction between cyclophilin A and prolactin receptor.

Syed F, Rycyzyn MA, Westgate L, Clevenger CV.

Endocrine. 2003 Feb-Mar;20(1-2):83-90.

PMID:
12668872
44.

The role of prolactin in mammary carcinoma.

Clevenger CV, Furth PA, Hankinson SE, Schuler LA.

Endocr Rev. 2003 Feb;24(1):1-27. Review.

45.
46.

The intranuclear prolactin/cyclophilin B complex as a transcriptional inducer.

Rycyzyn MA, Clevenger CV.

Proc Natl Acad Sci U S A. 2002 May 14;99(10):6790-5. Epub 2002 May 7.

47.

Prolactin receptor signal transduction.

Clevenger CV, Kline JB.

Lupus. 2001;10(10):706-18. Review.

PMID:
11721697
48.

An old epithelial cell never dies, it just agonesces away.

Clevenger CV.

Trends Endocrinol Metab. 2001 Jul;12(5):183-4.

PMID:
11397636
49.

Identification and characterization of the prolactin-binding protein in human serum and milk.

Kline JB, Clevenger CV.

J Biol Chem. 2001 Jul 6;276(27):24760-6. Epub 2001 May 3.

50.

Supplemental Content

Loading ...
Support Center